Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...

Omvoh was approved for its first IBD indication, moderately to severely active ulcerative colitis (“UC”), in 2023. The drug is currently approved for UC in 44 countries. The approval of Omvoh ...

"Eli Lilly reports positive data from trial of Omvoh for Crohn’s disease" was originally created and published by Clinical ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

Mark Genovese: Crohn’s disease is a chronic, inflammatory bowel disease associated with progressive bowel damage, disability, ...

Eli Lilly presents positive results from VIVID-2 open-label extension study of Omvoh to treat Crohn's disease at Crohn's and Colitis Congress: Indianapolis Monday, February 10, 20 ...

Omvoh is also approved in 44 countries for the treatment of moderately to severely active ulcerative colitis (UC) in adults. Omvoh is the first and only IL-23p19 antagonist to demonstrate long ...

Additional global regulatory submissions are planned. In UC, Omvoh is currently approved in 44 countries. "People living with Crohn's disease have shared with us how truly disruptive symptoms such ...

More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Omvoh works to reduce inflammation within the gastrointestinal ...